Granules India gets USFDA’s approval for Levetiracetam Tablets

14 Jun 2023 Evaluate

Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets USP, 250 mg, 500 mg, 750 mg, and 1,000 mg. bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keppra Tablets of UCB, Inc. (UCB).

Levetiracetam Tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and infants of age 1 month and older children with epilepsy; Myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy; Primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. 

Granules now has a total of 58 ANDA approvals from USFDA (56 Final approvals and 2 tentative approvals).The current annual U.S. market for Levetiracetam Tablets is around $247 million, according to MAT March 2023, IQVIA/IMS Health.  

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

411.00 0.00 (0.00%)
09-May-2024 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1540.15
Dr. Reddys Lab 6058.80
Cipla 1389.95
Zydus Lifesciences 1006.95
Lupin 1612.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.